MIAMI, August 7, 2025 — Leads & Copy — SAB BIO (Nasdaq: SABS) reported its second-quarter financial results, ending June 30, 2025, and provided updates on recent developments, including raising $175 million in an oversubscribed private placement. This funding, which included strategic investor Sanofi, extends the company’s operational runway to mid-2028.
The company achieved alignment with the FDA on the design of its Phase 2b SAFEGUARD study, evaluating SAB-142 for type 1 diabetes. The SAFEGUARD study is slated to begin in Q3 2025.
Samuel J. Reich, Chairman and CEO of SAB BIO, highlighted the significance of the $175 million capital raise, enabling the company to fully fund the SAFEGUARD study. He also noted the participation of top-tier biotech investors and Sanofi.
The funding will support the advancement of SAB-142, a multi-specific therapy, into a pivotal Phase 2b study in Q3 2025, with the aim of offering a disease-modifying therapy for patients with Stage 3 type 1 diabetes.
Recent corporate highlights include the securities purchase agreement on July 21, 2025, to raise $175 million. These funds will support the SAFEGUARD study, evaluating SAB-142 in newly diagnosed T1D patients aged 5-40. The company expects the proceeds to extend its cash runway into mid-2028.
SAB BIO issued shares of Series B nonvoting convertible preferred stock and warrants. The private placement closed on July 22, 2025, with further details available in SEC filings.
Clinical and regulatory updates include completing randomization of a Phase 1 study and enrolling T1D participants to assess SAB-142’s safety and tolerability. Final data is expected in Q4 2025. A Type B meeting with the FDA in May 2025 resulted in alignment on the SAFEGUARD study design, which is set to begin in Q3 2025.
Key financial figures for Q2 2025 include cash and equivalents of $5.7 million as of June 30, 2025, R&D expenses of $7.0 million, and a net loss of $10.1 million.
Contact:
Kaelan Hollon, Vice President of Communications, khollon@sab.bio
Kevin Gardner, LifeSci Advisors, kgardner@lifesciadvisors.com
Source: SAB BIO
